Goldman Sachs
ATOS icon

Goldman Sachs’s Atossa Therapeutics ATOS Stock Holding History

Goldman Sachs’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,330
Closed -$278K – 6326
2025
Q2 		$278K Buy
22,330
+9,802
+78% +$117K ﹤0.01% 5483
2025
Q1 		$126K Sell
12,528
-10,463
-46% -$127K ﹤0.01% 5737
2024
Q4 		$326K Buy
22,991
+6,382
+38% +$125K ﹤0.01% 5465
2024
Q3 		$379K Buy
16,609
+9,765
+143% +$197K ﹤0.01% 5201
2024
Q2 		$122K Sell
6,844
-35,060
-84% -$776K ﹤0.01% 5380
2024
Q1 		$1.13M Buy
+41,904
New +$673K ﹤0.01% 4262
2022
Q3 		– Sell
-4,285
Closed -$70K – 6250
2022
Q2 		$70K Sell
4,285
-2,536
-37% -$40K ﹤0.01% 5955
2022
Q1 		$128K Sell
6,821
-10,503
-61% -$213K ﹤0.01% 6025
2021
Q4 		$416K Buy
17,324
+3,486
+25% +$128K ﹤0.01% 5485
2021
Q3 		$676K Buy
13,838
+10,504
+315% +$611K ﹤0.01% 5014
2021
Q2 		$316K Sell
3,334
-917
-22% -$48.5K ﹤0.01% 5488
2021
Q1 		$135K Buy
+4,251
New +$155K ﹤0.01% 5763
2020
Q4 		– Sell
-1,420
Closed -$52K – 5476
2020
Q3 		$52K Buy
+1,420
New +$68.2K ﹤0.01% 5185
2016
Q3 		– Sell
-15
Closed -$12K – 7005
2016
Q2 		$12K Buy
+15
New +$12.2K ﹤0.01% 6825
2016
Q1 		– Sell
-13
Closed -$11K – 7073
2015
Q4 		$11K Buy
13
+1
+8% +$1.54K ﹤0.01% 6955
2015
Q3 		$24K Buy
+12
New +$30.8K ﹤0.01% 6986
2015
Q1 		– Sell
-10
Closed -$38K – 7064
2014
Q4 		$38K Sell
10
-14
-58% -$39.5K ﹤0.01% 6877
2014
Q3 		$86K Buy
24
+14
+140% +$68.9K ﹤0.01% 6640
2014
Q2 		$47K Sell
10
-5
-33% -$19.4K ﹤0.01% 6772
2014
Q1 		$68K Buy
15
+2
+15% +$11.8K ﹤0.01% 6500
2013
Q4 		$82K Hold
13
– – ﹤0.01% 6334
2013
Q3 		$191K Buy
+13
New +$170K ﹤0.01% 5898

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs's ATOS Position: Q3 2025 in Review

Goldman Sachs sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 22,330 shares — an estimated $278K sold.

Goldman Sachs first reported a position in ATOS in Q3 2013 and held it in 22 quarters. The position peaked at $1.13M in Q1 2024. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Goldman Sachs reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 22,330 Atossa Therapeutics shares in Q3 2025, an estimated $278K.
  • Goldman Sachs first reported a position in Atossa Therapeutics in Q3 2013 and held it in 22 quarters.
  • Goldman Sachs's Atossa Therapeutics position peaked at $1.13M in Q1 2024.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.